N
Nanopath
A molecular diagnostics company disrupting traditional testing methodologies
About Nanopath
Nanopath is a pioneering startup in the field of molecular diagnostics, with a specific focus on women's health. The company aims to revolutionize traditional testing methods by providing detailed and actionable health information within a single office visit. This approach is designed to address the often overlooked complexities of female biology and the emerging healthcare models.
Nanopath operates in the healthcare market, specifically in the molecular diagnostics sector. Its primary clients are healthcare providers who require accurate and rapid diagnostic information for their patients, particularly women. The company's business model is centered around the development and commercialization of its novel diagnostic technologies. It generates revenue through the sale of these technologies to healthcare providers and institutions.
The company was founded as a spin-off from the Thayer School of Engineering at Dartmouth, in partnership with Dartmouth Hitchcock Medical Center. Nanopath's technology platform is designed to detect viral, bacterial, and fungal pathogens without the need for nucleic acid amplification, a process that makes the DNA in a sample easier to detect. While the company's initial focus is on women's infectious diseases, the technology has potential applications beyond this area.
In summary, Nanopath is a healthcare technology startup that aims to improve women's health by providing more accurate and actionable diagnostic information. The company envisions its platform as the go-to system for routine women's health screening at the point-of-care.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 29
- Open positions
- 5
- Dealroom signal
- 86.3/100
- Industry
- Health, Wellness Beauty
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Marketplace & ecommerce
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Aug 2026 | $200K | — | MassVentures | ↗ |
| GRANT✓Other financing | May 2024 | $4M | — | US National Science Foundation · National Institutes of Health | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Nanopath is 460 monthly website visits, down 96.2% over the last three months. Nanopath's team grew 26.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
US National Science Foundation
National Institutes of Health
MassVentures
Series A4 investors entered at this stage
Norwest Venture Partners
SV Health Investors
Green D Ventures
GingerBread Capital
Other known investors4 additional known investors
Dartmouth College
Alumni Ventures
Creative Destruction Lab
Undeterred Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanopath on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanopath’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







